(NASDAQ: BEAM) Beam Therapeutics's forecast annual revenue growth rate of -50.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Beam Therapeutics's revenue in 2024 is $377,709,000.On average, 6 Wall Street analysts forecast BEAM's revenue for 2024 to be $5,082,621,093, with the lowest BEAM revenue forecast at $1,633,154,280, and the highest BEAM revenue forecast at $8,165,771,400. On average, 5 Wall Street analysts forecast BEAM's revenue for 2025 to be $4,825,317,636, with the lowest BEAM revenue forecast at $1,633,154,280, and the highest BEAM revenue forecast at $6,570,179,668.
In 2026, BEAM is forecast to generate $3,300,196,511 in revenue, with the lowest revenue forecast at $30,213,354 and the highest revenue forecast at $6,570,179,668.